Anaesthesia Drugs Market Forecasts to 2028 – Global Analysis By Route of Administration (Injection Anesthesia Drugs, Inhalation Anesthesia Drugs, Intravenous Anesthesia Drugs, Topical Anesthesia Drugs), Anaesthesia Type (Regional Anesthesia, Local Anesthe

Anaesthesia Drugs Market Forecasts to 2028 – Global Analysis By Route of Administration (Injection Anesthesia Drugs, Inhalation Anesthesia Drugs, Intravenous Anesthesia Drugs, Topical Anesthesia Drugs), Anaesthesia Type (Regional Anesthesia, Local Anesthesia, General Anesthesia, Sedation), Drug Type (Local Anesthesia Drugs, General Anesthesia Drugs), Application (Plastic Surgery, Dental Surgery, General Surgery, Cosmetic Surgery), End User (Specialty Clinics, Hospitals, Ambulatory Surgical Centers, Pharmaceutical Companies), and By Geography

According to Stratistics MRC, the Global Anaesthesia Drugs Market is accounted for $7.58 billion in 2022 and is expected to reach $10.52 billion by 2028 growing at a CAGR of 5.6% during the forecast period. Anaesthesia is a medical procedure that allows patients to be pain-free during surgery. Anaesthetics are administered by injection, inhalation, topical lotion, spray, eye drops, or a skin patch, depending on the type of pain relief required. The use of anesthesia drugs causes a momentary loss of feeling or awareness. They are split into two categories such as general anesthetics, which produce a reversible loss of consciousness, and local anesthetics, which cause a reversible loss of feeling for a specific area of the body but do not impact consciousness. During surgery, anesthesia medication is used to alleviate discomfort. Depending on the surgery and the patient’s health, several types and degrees of anesthesia may be used. New technology (such as wireless communication) has helped to enhance anesthesia distribution and patient monitoring during surgeries.

According to the American Society of Plastic Surgeons, in 2020, 2.3 million cosmetic surgical procedures, 13.2 million cosmetic minimally invasive procedures, and 6.8 million reconstructive procedures were performed in the United States 2020, representing a 3% increase over 2019. This indicates the rising number of surgeries, which ultimately results in the rising demand for anesthesia drugs. Moreover, according to the article 'Trauma of Major Surgery' published in the National Center for Biotechnology Information (NCBI) in July 2020, globally, a staggering 310 million major surgeries are performed each year. Similarly, according to the article titled 'Incidence and Cumulative Risk of Major Surgery in Older Persons in the United States published in July 2021, in the United States, Nearly nine major surgeries were performed annually for every 100 older persons, and more than 1 in 7 Medicare beneficiaries underwent a major surgery over five years, representing nearly 5 million unique older people.

Market Dynamics:

Driver:

Growing number of surgeries, rising elderly population and advances in technology

One of the major factors driving the anaesthetics market is the increase in the number of surgeries performed that use anaesthetics during the surgical procedure. An increase in surgeries is primarily due to the increasing incidents of traumatic injuries and accidents requiring surgical procedures. World Health Organization's Global status report on road safety 2018 shows that there are 1.35 million road accidents every year, with 64 deaths per 100,000 vehicles. Additionally, advances in technology in the delivery of Drugs, the development of specifically targeted medicines, the development of devices to monitor patients' physiological parameters during and after Anesthesia, and reduced side effects of anaesthetics are the driving factors that will boost the market growth. By 2050, one out of four people living in Europe and Northern America could be 65 years or older, according to the Department of Economic and Social Affairs of the United Nations. With an increase in the elderly population, chronic diseases such as cardiovascular and neurological are on the rise in older populations, further increasing the need for Anesthesia Drugs.

Restraint:

Adverse effects of anesthetic drugs

The side effects of anesthetic drugs during and after surgery are predicted to restrain the market growth in the future. Common side effects observed are ringing in the ears, dizziness, numbness, twitching, and a metallic taste. In extreme cases, it can cause seizures, low blood pressure, slowed heart rate, and breathing problems. Most people will not experience any long-term side effects. However, geriatric populations are more prone to side effects that last longer than a few days. Side effects are high if the patient has certain pre-existing conditions such as reactions to anesthesia, sleep apnea, seizures, obesity, high blood pressure, diabetes, heart disease, lung disease, kidney disease, or drug allergies. Additionally, side effects such as nausea, vomiting, pruritus, urinary retention, sedation, and delayed respiratory depression can occur. Unintended intraoperative awareness is another consequence, in rare cases where patients report a state of awareness during the surgery, after the point where the anesthetic should cause numbness or no sensation. Some patients are conscious during the procedure, and some may even feel pain. Thus, after the surgery, patients may suffer from pain. The duration of action of these drugs can be prolonged both by increasing the dose and by a continuous infusion of the drug, leading to dose-dependent effects on the cardiovascular system and/or central nervous system (CNS).

Opportunity:

Increasing technological advancements

The surging number of surgical procedures globally is predicted to provide opportunities to the market during the forecast period. There are innovative and technological advancements in anesthetics, which accelerate the market growth. However, the future of the market is challenging owing to stagnant reimbursement procedures, the command for safety and quality, and claims on the evidence to drive the practice. As per the research article published in the Journal of Anesthesia 2019, the emergence of ultrasound-guided regional anesthesia has soared rapid growth in various nerve block techniques, with for inter fascial plane blocks. However, only numerous anesthetists may know these novel blocks, while the remainder may see regional anesthesia becoming too complex and intimidating. Hence, training sessions for the anesthetists will be required, playing a fundamental role in enhancing the use of anesthetic drugs in the future. Furthermore, according to the research article published in the Saudi Journal of Anesthesia, 2020, adjuvants to local anesthetics are budding in anesthesiology, where newer agents and techniques are added to develop the efficacy and safety of analgesia used. Research continues on agents capable of prolonging the effect of local anesthetics without neurotoxicity or deleterious effects. Robotic anesthesia has attracted many manufacturers due to its potential to deliver manual gestures with precision.

Threat:

Unintentional intraoperative awareness

During the surgical process when general Anesthesia is given, approximately one or two people out of every 1000 may be unaware that they are partially awake. There is very little chance of experiencing pain, but this can also occur. Since people are being given relaxation Drugs before surgeries, they cannot move or communicate their pain or awareness to the doctors. There is the possibility that this will cause patients long-term psychological problems, similar to post-traumatic stress disorder. This is called unintentional intraoperative awareness and it is one of the major challenges to the Anesthesia drugs market.

Covid-19 Impact

A slight decline in the demand for anesthesia drugs was observed in 2020 as a result of the pandemic, causing delays or cancellations of surgeries. According to a study published in the British Journal of Surgery, approximately 28.4 million elective surgeries were cancelled or postponed globally in May 2020 due to the disruption of hospital services caused by COVID-19. Nevertheless, as social activities are resuming, all elective surgeries that were delayed, are being performed now, which means that anesthesia drugs are being consumed in greater quantities resulting in the market gradually picking up market growth. Post covid 19, the need for anesthesia drugs will grow more.

The general anesthesia drugs segment is expected to be the largest during the forecast period

The general anesthesia drugs segment is anticipated to have a lucrative growth, due to increase in the number of general and emergency surgeries which require the use of general anesthesia drugs since they helped doctors to create individualized anaesthetic plans that balance the patient's history with the anticipated surgical plan that maximizes patient safety.

The intravenous anesthesia drugs segment is expected to have the highest CAGR during the forecast period

The intravenous anesthesia drugs segment is anticipated to witness the fastest CAGR growth during the forecast period, as it offers various advantages such as more accurate dose delivery, better patient safety, lower rates of (postoperative nausea, vomiting, urinary retention, and malignant hyperthermia (a rare but serious side effect of general Anesthesia)), reduced risk of blood clots and pulmonary emboli (blood clots that move to the lungs). Furthermore, intravenous anesthesia medicines can be more precise which amounts to a higher safety level.

Region with highest share:

North America is projected to have the largest market share during the forecast period, due to increasing aging population with growing chronic conditions, rising number of surgeries, and advancements in anesthesia technologies. The United States is the largest regional market in the world. With the emergence of COVID-19, the United States faced heavy shortages of vital anesthesia drugs, particularly dexmedetomidine, midazolam, propofol, and neuromuscular blocking agents. As a result, many companies are ramping up their production of anesthesia drugs. Around 40-50 million out of 310 million major surgeries worldwide are performed every year in the United States alone.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the rapidly expanding healthcare infrastructure, the presence of major players, the adoption of anesthesia drugs is increasing rapidly in this region, increasing cases of chronic diseases, load of the aging population, and related diseases increasing the procurement of local anesthetics for surgery and management of postoperative pain.

Key players in the market

Some of the key players profiled in the Anaesthesia Drugs Market include F. Hoffmann-La Roche Ltd, Fresenius SE & Co. KGaA, AbbVie Inc, Pfizer Inc., Boehringer Ingelheim International GmbH, Dr. Reddy's Laboratories, Baxter International, Inc., Novartis AG, Abbott Laboratories, B. Braun Melsungen AG, Astrazeneca PLC, GlaxoSmithKline plc, Hikma Pharmaceuticals PLC, Piramal Enterprises Limited, Teva Pharmaceutical Industries Limited, Mylan NV, Johnson & Johnson, Merck, and Eisai Inc.

Key Developments:

In July 2021, Hikma Pharmaceuticals PLC (Hikma), an international pharma company, launched Succiniylcholine Chloride Injection, USP 20mg/mL in the US, through its US affiliate, Hikma Pharmaceuticals USA Inc. In the treatment of COVID-19 patients Succinylcholine Chloride Injection, USP plays an important role. It is used to facilitate tracheal intubation as well as to relax skeletal muscles during a procedure or while on mechanical ventilation.

In November 2020, Pfizer announced the completion of merging its Upjohn business with Mylan N.V. to form Viatris Inc., where Pfizer would hold 57% of the shares of the company.

In August 2020, Teva Pharmaceuticals announced a strategic partnership with a biopharmaceutical company called Alvotech for the commercialization of five biosimilar products in the United States.

In August 2020, B. Braun and Royal Philips announced that their Onvision needle tip tracking technology for regional anesthesia got the 501(k) clearance from the United States Food and Drug Administration.

Route of Administrations Covered:
• Injection Anesthesia Drugs
• Inhalation Anesthesia Drugs
• Intravenous Anesthesia Drugs
• Topical Anesthesia Drugs

Anaesthesia Types Covered:
• Regional Anesthesia
• Local Anesthesia
• General Anesthesia
• Sedation

Drug Types Covered:
• Local Anesthesia Drugs
• General Anesthesia Drugs

Applications Covered:
• Plastic Surgery
• Dental Surgery
• General Surgery
• Cosmetic Surgery

End Users Covered:
• Specialty Clinics
• Hospitals
• Ambulatory Surgical Centers
• Pharmaceutical Companies

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements